Transthyretin Stabilizer Drug Class List

Drugs in Drug Class: Transthyretin Stabilizer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride	TABLET;ORAL	216540-001	Nov 22, 2024		RX	Yes	Yes	11,260,047		Y
Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride	TABLET;ORAL	216540-001	Nov 22, 2024		RX	Yes	Yes	10,842,777
Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride	TABLET;ORAL	216540-001	Nov 22, 2024		RX	Yes	Yes
Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride	TABLET;ORAL	216540-001	Nov 22, 2024		RX	Yes	Yes	11,919,865
Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride	TABLET;ORAL	216540-001	Nov 22, 2024		RX	Yes	Yes

Market Dynamics and Patent Landscape for Transthyretin Stabilizer Drugs

Last updated: January 23, 2026

---

Summary

The transthyretin (TTR) stabilizer class targets amyloidosis associated with transthyretin protein misfolding, primarily used in treating transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN). The market has experienced significant growth driven by increased diagnostic awareness, expanding patient populations, and approval of key drugs. The patent landscape is characterized by towering patent protections for pioneering agents such as tafamidis, alongside evolving generics and biosimilars, shaping future competition and innovation.

---

Market Overview: Demand Drivers and Trends

Global Market Size and Forecast

Year	Market Size (USD Billion)	CAGR (2022-2028)
2022	1.2	—
2023	1.35	12.5%
2024	1.52	12.6%
2025	1.71	12.3%
2026	1.92	12.3%
2027	2.16	12.5%
2028	2.43	12.5%

Source: Market Research Future (2023)

Main Growth Drivers

• Increased Diagnostic Capabilities: Advanced imaging, genetic testing, and amyloid PET scans facilitate early detection.
• Unmet Medical Need: Limited treatment options prior to approval of stabilizers.
• Aging Population: Higher prevalence of ATTR amyloidosis among the elderly.
• Regulatory Approvals: Rapid approval and expanded indications for transthyretin stabilizers.
• Pipeline Expansion: New molecules and combination therapies.

Regional Market Distribution

Region	Market Share (2022)	Growth Dynamics
North America	55%	Leading, owing to high diagnosis rates and robust R&D
Europe	25%	Growing with increased awareness and approvals
Asia-Pacific	12%	Fastest growth due to untapped potential
Rest of World	8%	Emerging markets

---

Key Drugs in the Transthyretin Stabilizer Class

Drug	Developer	Approval Year	Indications	Mechanism	Patent Status
Tafamidis (Vyndaqel®, Vyndamax®)	Pfizer (US), EA Pharma (Japan), others	2019 (US), 2011 (Europe)	ATTR-PN, ATTR-CM	Selective TTR stabilizer	Patent until 2030 (US), 2031 (EU)
Diflunisal	Off-label use	Approved (NSAID)	Experimental ATTR stabilization	Non-selective TTR stabilizer	Generic versions available

Note: Tafamidis is the first FDA-approved TTR stabilizer, representing a leading position.

---

Patent Landscape Analysis

Patent Expiry Timeline for Key Drugs

Patent	Filing Year	Expiry Year	Patent Type	Coverage Scope
Tafamidis	2000	2030 (US), 2031 (EU)	Compound formulation, use patents	Composition of matter, methods of treatment
Diflunisal	1950s	Generic versions available since early 2000s	Formulation	Dosage forms, formulations

Source: PatentScope, Thomson Innovation (2023)

Patent Strategies and Litigation Trends

• Extension of Patent Term: Use of "secondary patents" on formulations, delivery systems, and indications.
• Orphan Drug Exclusivity: Protects market in rare disease settings.
• Patent Challenges: Multiple generic manufacturers challenged tafamidis patents; courts upheld patent rights in key jurisdictions.

Emerging Patent Filings

• Focused on novel TTR stabilizer molecules with enhanced efficacy.
• Combination therapies: Patents targeting synergistic effects with other amyloidosis drugs.
• Biologic approaches: Patents on monoclonal antibodies and peptide-based stabilizers.

---

Competitive Landscape

Top Players	Market Share (Estimated 2022)	Key Patent Assets	Pipeline Status
Pfizer	~60%	Tafamidis patents, formulations	Multiple phase 2/3 trials
Alnylam	~20%	Gene-silencing approaches	Late-stage clinical trials
Akcea Therapeutics	~10%	TTR stabilizers & silencers	Ongoing R&D
Others	~10%	Generic competitors, biotech innovations	Emerging formulations & delivery methods

---

Comparison with Alternative Therapies

Therapy Class	Mechanism	Key Drugs	Market Share	Patent Status	Indications
Gene-silencing (RNAi)	Reduce TTR production	Patisiran, Vutrisiran	Growing	Patents expiring 2035+	ATTR-PN
CRISPR-based	Gene editing	Under clinical development	Early stage	Pending patents	Potential future
Stabilizers	Stabilize TTR tetramer	Tafamidis, AG10	Dominant	Active patents	ATTR amyloidosis

Note: Stabilizers remain first-line treatments due to established efficacy and patent protections.

---

Regulatory Policies Impacting the Landscape

Policy Area	Impact	Key Regulations/Guidelines
Patent Term Extensions	Extend exclusivity	U.S. Patent Term Extension Act, Supplementary Protection Certificates (EU)
Orphan Drug Designation	Data exclusivity benefits	FDA, EMA policies
Market Authorization	Accelerated approvals for unmet needs	Priority review, Breakthrough Therapy designation
Generic & Biosimilar Regulations	Facilitate entry post-patent expiry	Hatch-Waxman Act (US), Biosimilar regulations (EU, US)

---

Future Outlook

• Innovations in Molecules: Development of next-generation stabilizers with longer half-life, improved bioavailability.
• Combination Regimens: Potential for combination with gene silencing agents, enhancing treatment efficacy.
• Biosimilar & Generics Entry: Patent expirations around 2030 open opportunities for biosimilar development.
• Emerging Markets: Expansion driven by increased awareness and improved healthcare infrastructure.

---

Key Regulatory and Patent Considerations

Consideration	Implication
Patent Expiry Dates	Markets will face generic competition post-expiry, impacting pricing and market share
Patent Challenges	Intellectual property disputes can delay generic entry
Patent Extensions	Companies may seek legal extensions (e.g., patent term extensions)
Orphan Drugs	Incentives for innovation but limited competition during exclusivity

---

Summary of the Patent Landscape and Market Trends

Aspect	Observation
Patent protections	Strong until at least 2030-2032 for flagship drugs like tafamidis
Innovation pipeline	Focused on novel molecules, formulations, and combination therapies
Competition	Growing from generics, biosimilars, and emerging biotech startups
Regulatory environment	Supportive of innovation via expedited pathways, but patent challenges persist

---

Key Takeaways

• The transthyretin stabilizer market is characterized by robust patent protections for leading drugs, particularly tafamidis, which extends until at least 2030.
• The expanding patient population, driven by aging and improved diagnostics, fuels growth prospects.
• Patent litigation and strategic patent filings shape competitive dynamics; innovators seek patent extensions and new formulations to maintain market dominance.
• The transition towards combination therapies and alternative modalities (RNAi, gene editing) may reshape the therapeutic landscape.
• Emerging markets present new opportunities owing to increasing awareness and healthcare expansion.

---

FAQs

Q1: When do key patents for tafamidis expire, and what does this mean for competitors?
Answer: In the U.S., tafamidis patents are expected to expire around 2030, with European patents extending to 2031. Post-expiry, generic and biosimilar manufacturers can enter the market, intensifying price competition.

Q2: How do patent strategies protect innovation in the transthyretin stabilizer class?
Answer: Companies file patents on the molecule itself, specific formulations, methods of use, delivery systems, and combination therapies to extend exclusivity and defend against generic entry.

Q3: What are the main obstacles for new entrants in this domain?
Answer: High R&D costs, complex patent litigation, the need for clinical validation, and regulatory hurdles pose significant barriers. Patent thickets may also complicate the market entry.

Q4: How does the regulatory environment influence the patent landscape?
Answer: Policies like orphan drug incentives, patent term extensions, and accelerated approval pathways promote innovation but can be challenged through patent oppositions or litigation.

Q5: What trends are anticipated for the next five years in TTR stabilizer therapeutics?
Answer: Expect increased pipeline activity focusing on next-generation molecules, approval of combination therapies, and entry of biosimilars post-patent expiry, intensifying competition and potentially lowering prices.

---

References

1. Market Research Future. (2023). "Global Transthyretin Amyloidosis Market Outlook."
2. PatentScope Database. (2023). Patent filings and expiry data.
3. U.S. Food and Drug Administration. (2019). FDA approval for Vyndaqel.
4. EMA. (2011). European approval of tafamidis for ATTR amyloidosis.
5. Thomson Innovation. (2023). Patent landscape and litigation case studies.

---

This comprehensive review supports informed decision-making in investment, R&D, and strategic business alignment within transthyretin stabilizer therapeutics.